Cybin remains in a high-risk, pre-revenue development phase, characterized by significant quarterly operating losses that peaked at $58.3 million in 2025Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q1 2026Latest Feb 9, 2026 | -$0.38+28.3% vs -$0.53 | — vs — |
Q4 2025 Nov 13, 2025 | -$1.39-87.8% vs -$0.74 | — vs — |
Q3 2025 Aug 14, 2025 | -$1.10-115.7% vs -$0.51 | — vs — |
Q3 2025 Jun 30, 2025 | -$1.02-100.0% vs -$0.51 | — vs — |
Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company's auditor, board size, corporate name and director elections.
Cybin NASDAQ: HELP executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright's 28th Annual Global Investment Conference.
Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company's mental health treatment pipeline.
Benchmark HELP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Helus Pharma Inc. (HELP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.96 | $555.38M | -2.56 | -9561.61% | 329.09% | -70.99% | — | |
| $8.61 | $1.16B | -5.26 | — | — | -212.85% | — | |
| $1.33 | $1.5M | -0.33 | — | -8269.53% | -81.74% | — | |
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — | |
| $1.42 | $847.76K | -0.65 | — | — | -168.05% | — | |
| $0.28 | $31.2M | 14.98 | -5.32% | 1.22% | 1.54% | 6.32% |
Helus Pharma Inc. (HELP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when HELP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Helus Pharma Inc. (HELP) stock FAQ — growth, dividends, profitability & financials explained
Helus Pharma Inc. (HELP) reported $-44.7M in revenue in fiscal year 2026.
Helus Pharma Inc. (HELP) revenue fell by 9561.6% in fiscal year 2026, compared with the prior fiscal year.
No. Helus Pharma Inc. (HELP) reported a net loss of $183.3M over the trailing twelve months.
Helus Pharma Inc. (HELP) had a return on equity (ROE) of -71.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Helus Pharma Inc. (HELP) had negative free cash flow of $154.6M over the trailing twelve months.
